BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 36928864)

  • 21. Entecavir and other nucleos(t)ide analogs prophylaxis in hepatitis B virus-related liver transplantation: long-term efficacy and safety.
    Darweesh SK; Gad AA; Akroof K; ElLatif ZA
    Eur J Gastroenterol Hepatol; 2019 May; 31(5):607-612. PubMed ID: 30724767
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transplantation of hepatitis B surface antigen-positive livers into hepatitis B virus-positive recipients and the role of hepatitis delta coinfection.
    Franchello A; Ghisetti V; Marzano A; Romagnoli R; Salizzoni M
    Liver Transpl; 2005 Aug; 11(8):922-8. PubMed ID: 16035057
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Entecavir Combined With Short-term Hepatitis B Immunoglobulin in Preventing Hepatitis B Virus Recurrence in Liver Transplant Recipients.
    Zheng H; Zhu Z; Wang N; Qin J; Guo Y; Xu Z; Li X; Qi C; Yuan X; Wu W; Wang J; Liu L; Nashan B
    Transplant Proc; 2023 Mar; 55(2):408-412. PubMed ID: 36907782
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Escape hepatitis B virus mutations in recipients of antibody to hepatitis B core antigen-positive liver grafts receiving hepatitis B immunoglobulins.
    Roche B; Roque-Afonso AM; Sebagh M; Delvart V; Duclos-Vallee JC; Castaing D; Samuel D
    Liver Transpl; 2010 Jul; 16(7):885-94. PubMed ID: 20583085
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prophylaxis against hepatitis B virus recurrence after liver transplantation: a registry study.
    Shen S; Jiang L; Xiao GQ; Yan LN; Yang JY; Wen TF; Li B; Wang WT; Xu MQ; Wei YG
    World J Gastroenterol; 2015 Jan; 21(2):584-92. PubMed ID: 25593480
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recurrence-free long-term survival after liver transplantation for hepatitis B using interferon-alpha pretransplant and hepatitis B immune globulin posttransplant.
    Tchervenkov JI; Tector AJ; Barkun JS; Sherker A; Forbes CD; Elias N; Cantarovich M; Cleland P; Metrakos P; Meakins JL
    Ann Surg; 1997 Sep; 226(3):356-65; discussion 365-8. PubMed ID: 9339942
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discontinuation of Passive Immunization Is Safe after Liver Transplantation for Combined HBV/HDV Infection.
    Ossami Saidy RR; Sud I; Eurich F; Aydin M; Postel MP; Dobrindt EM; Pratschke J; Eurich D
    Viruses; 2021 May; 13(5):. PubMed ID: 34068217
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nucleoside plus nucleotide analogs and cessation of hepatitis B immunoglobulin after liver transplantation in chronic hepatitis B is safe and effective.
    Wesdorp DJ; Knoester M; Braat AE; Coenraad MJ; Vossen AC; Claas EC; van Hoek B
    J Clin Virol; 2013 Sep; 58(1):67-73. PubMed ID: 23880162
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Failure of a reinforced triple course of hepatitis B vaccination in patients transplanted for HBV-related cirrhosis.
    Angelico M; Di Paolo D; Trinito MO; Petrolati A; Araco A; Zazza S; Lionetti R; Casciani CU; Tisone G
    Hepatology; 2002 Jan; 35(1):176-81. PubMed ID: 11786974
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HBIg discontinuation with maintenance oral anti-viral therapy and HBV vaccination in liver transplant recipients.
    Weber NK; Forman LM; Trotter JF
    Dig Dis Sci; 2010 Feb; 55(2):505-9. PubMed ID: 19802696
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety of complete and sustained prophylaxis withdrawal in patients liver-transplanted for HBV-related cirrhosis at low risk of HBV recurrence.
    Lenci I; Tisone G; Di Paolo D; Marcuccilli F; Tariciotti L; Ciotti M; Svicher V; Perno CF; Angelico M
    J Hepatol; 2011 Sep; 55(3):587-593. PubMed ID: 21251938
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Retransplantation of patients with severe posttransplant hepatitis B in the first allograft.
    Ishitani M; McGory R; Dickson R; Caldwell S; Bickston S; McCullough C; Pruett T; Terrault N; Roberts J; Ascher N; Wright T; Lake J
    Transplantation; 1997 Aug; 64(3):410-4. PubMed ID: 9275104
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term outcome of patients with lamivudine after early cessation of hepatitis B immunoglobulin for prevention of recurrent hepatitis B following liver transplantation.
    Yuefeng M; Weili F; Wenxiang T; Ligang X; Guiling L; Hongwei G; Wencai L; Xiaoguang W; Wei M; Zhongyi F
    Clin Transplant; 2011; 25(4):517-22. PubMed ID: 20560989
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low-dose short-term hepatitis B immunoglobulin with high genetic barrier antivirals: the ideal post-transplant hepatitis B virus prophylaxis?
    Choudhary NS; Saraf N; Saigal S; Mohanka R; Rastogi A; Goja S; Menon PB; Soin AS
    Transpl Infect Dis; 2015 Jun; 17(3):329-33. PubMed ID: 25682715
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Section 14. Combination of entecavir plus low-dose on-demand hepatitis B immunoglobulin is effective with very low hepatitis B recurrence after liver transplantation.
    Hu TH; Chen CL; Lin CC; Wang CC; Chiu KW; Yong CC; Liu YW; Eng HL
    Transplantation; 2014 Apr; 97 Suppl 8():S53-9. PubMed ID: 24849836
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation.
    Naoumov NV; Lopes AR; Burra P; Caccamo L; Iemmolo RM; de Man RA; Bassendine M; O'Grady JG; Portmann BC; Anschuetz G; Barrett CA; Williams R; Atkins M
    J Hepatol; 2001 Jun; 34(6):888-94. PubMed ID: 11451173
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Living related liver transplantation for hepatitis B-related liver disease without hepatitis B immune globulin prophylaxis.
    Wadhawan M; Gupta S; Goyal N; Taneja S; Kumar A
    Liver Transpl; 2013 Sep; 19(9):1030-5. PubMed ID: 23788470
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early Introduction of Subcutaneous Hepatitis B Immunoglobulin Following Liver Transplantation for Hepatitis B Virus Infection: A Prospective, Multicenter Study.
    De Simone P; Romagnoli R; Tandoi F; Carrai P; Ercolani G; Peri E; Zamboni F; Mameli L; Di Benedetto F; Cillo U; De Carlis L; Lauterio A; Lupo L; Tisone G; Prieto M; Loinaz C; Mas A; Suddle A; Mutimer D; Roche B; Wartenberg-Demand A; Niemann G; Böhm H; Samuel D
    Transplantation; 2016 Jul; 100(7):1507-12. PubMed ID: 27023394
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term clinical and virological outcome after liver transplantation for cirrhosis caused by chronic delta hepatitis.
    Samuel D; Zignego AL; Reynes M; Feray C; Arulnaden JL; David MF; Gigou M; Bismuth A; Mathieu D; Gentilini P
    Hepatology; 1995 Feb; 21(2):333-9. PubMed ID: 7843702
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-virus prophylaxis withdrawal may be feasible in liver transplant recipients whose serum HBeAg and HBV DNA are negative.
    Geng L; Lin BY; Shen T; Guo H; Ye YF; Zheng SS
    Hepatobiliary Pancreat Dis Int; 2016 Jun; 15(3):316-8. PubMed ID: 27298109
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.